Perrigo Israel

Parent Company

PERRIGO COMPANY PLC (NYSE: PRGO),
(TASE: PRGO) 

Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing Quality, Affordable Self-Care Products that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter (“OTC”) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Perrigo is the world’s largest provider of OTC self-care products and infant formulas for the store brand market. The Company also is a leading marketer of branded OTC products throughout Europe, as well as a leading producer of ’extended topical’ prescription drugs in the U.S. Perrigo, headquartered in Ireland, sells its consumer products primarily in North America, Europe, Israel, Australia and China. Perrigo has approximately 11,200 employees worldwide.

Perrigo Israel

Perrigo Israel develops, manufactures and markets generic prescription pharmaceuticals and OTC self-care products.

Perrigo Israel employs approximately 900 highly trained team members, including Ph.D.s and life sciences professionals. More than two-thirds of Perrigo Israel’s net sales are generated from exports and its main operational center is in Yerucham with its logistic center and main office located in Shoham.

Perrigo Israel – Israeli Market Operations

Perrigo Israel is a diversified business that imports, markets and distributes OTC self-care products, branded and generic pharmaceuticals, and medical diagnostic equipment. Perrigo Israel distributes products in Israel for several major healthcare companies including Aspen, Grifols, GSK, Sandoz, Siemens Healthcare, Pierre Fabre and Celltrion.

Generating Financial Strength

Perrigo’s shares are dually listed on the New York Stock Exchange (NYSE), and the Tel Aviv Stock Exchange (TASE). The Company is undergoing a three-year transformation from a healthcare to a consumer self-care company with the long-term goal of generating 3% net sales growth, 5% adjusted operating income growth and 7% adjusted earnings per share growth.